Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients
Creators: name: Domínguez-Sosa, María Sandra
name: Cabrera-Ramírez, María Soledad
name: del Carmen Marrero-Ramos, Miriam
name: Dávila-Quintana, Delia
name: Cabrera-López, Carlos
name: Cuervo, Heleia González
name: del Rosario, Jesús Javier Benítez
name: Carrillo-Díaz, Teresa
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Ecology
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Dupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes in CRSwNP and asthma patients, treated with dupilumab over time. A collateral secondary objective was to analyse the effects over time of dupilumab in patients with and without aeroallergen sensitization. Single-centre retrospective observational study on severe CRSwNP patients treated with dupilumab. Nasal polyp score (NPS), visual analogue scale (VAS) symptom score, sinonasal outcome test (SNOT-22), aeroallergen sensitization, total serum IgE levels, and blood eosinophil counts were assessed at baseline and after 4, 6 and 12 months. 42 patients were included, 40 (95.2%) had asthma. Twenty-one (50%) patients received dupilumab without prior biological treatment (Group A: naive) and 50% switched to dupilumab from previous biological treatment (Group B: pre-treated). NPS, VAS symptoms, SNOT-22 improved significantly after 12 months treatment in both groups of patients (<i>p</i> &lt; 0.001). After 12 months, VAS overall symptom score showed a significant reduction from 6 (IQR, 4.6–8.6) and 6 (IQR, 3.8–7.1) for Group A and Group B patients respectively, to 1.2 (IQR, 0.8–2.7) and 1.2 (IQR, 0.2–2.5); NPS from 6 (IQR, 4.0–7.0) and 5 (IQR, 3.5–6.0), respectively, to 1 (IQR, 0.0–2.0) and 0 (IQR, 0.0–3.0) and SNOT-22 from 64 (IQR, 56–78) and 71 (IQR, 47.5–76.0) respectively, to 5.5 (IQR, 4–21) and 6 (IQR, 4–15). IgE reduced from 57 to 22.1 and from 46.9 to 30.2 in Group A and Group B respectively (<i>p</i> &lt; 0.001). Dupilumab improves symptom severity, polyp size, and health-related quality of life, regardless of the presence or absence of comorbid aeroallergen sensitization and previous administration of biologic therapy. Dupilumab proved to be effective in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).We observed that dupilumab for CRSwNP leads to a very rapid improvement in polyps, symptoms, and quality of life, regardless of previous biologic treatment status and presence or absence of allergic rhinitis.VAS, SNOT-22 and NPS may be established as outcome markers in everyday clinical practice during dupilumab treatment. Dupilumab proved to be effective in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). We observed that dupilumab for CRSwNP leads to a very rapid improvement in polyps, symptoms, and quality of life, regardless of previous biologic treatment status and presence or absence of allergic rhinitis. VAS, SNOT-22 and NPS may be established as outcome markers in everyday clinical practice during dupilumab treatment.